Reglan and Tardive Dyskinesia: What the Research Shows

From General Health Awareness to Occupational Exposure

If you or a loved one takes Reglan and has noticed uncontrollable facial or body movements, you may be concerned about tardive dyskinesia. Decades of medical literature have established a clear link between prolonged metoclopramide use and this movement disorder. This page reviews the patterns reported in research studies and what they mean for monitoring and management.

The Medical Link Between Reglan and Tardive Dyskinesia

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent used to treat nausea, vomiting, and gastroparesis (https://pubmed.ncbi.nlm.nih.gov/34712535/). Its mechanism of action, while effective for these conditions, can lead to extrapyramidal side effects, including tardive dyskinesia (TD) (https://pubmed.ncbi.nlm.nih.gov/34712535/). TD is a hyperkinetic movement disorder caused by the use of dopamine receptor-blocking agents (DRBAs), a category that includes metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34703232/). The condition is characterized by involuntary movements of the face, limbs, and trunk, and is associated with increased comorbidities, social stigmatization, and impaired physical and mental health (https://pubmed.ncbi.nlm.nih.gov/34703232/). The U.S. Food and Drug Administration (FDA) has issued a boxed warning for Reglan regarding the risk of TD. The warning states that metoclopramide, including Reglan, can cause TD, a potentially irreversible serious movement disorder (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The risk of developing TD increases with duration of treatment and total cumulative dosage (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Reglan is contraindicated in patients with a history of TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). The FDA advises using Reglan for the shortest duration of treatment and periodically reassessing the need for continued treatment (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with symptomatic, documented gastroesophageal reflux, the maximum duration of Reglan treatment is 12 weeks (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). For patients with diabetic gastroparesis, a total duration of treatment longer than 12 weeks should be avoided; if longer-term use is unavoidable, routine monitoring for signs and symptoms of TD is recommended (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

Clinical Presentation and Risk Factors

The clinical presentation of TD includes potentially irreversible and disfiguring involuntary movements of the face or tongue, and sometimes of the trunk and/or extremities (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Metoclopramide may suppress or partially suppress the signs of TD, potentially delaying diagnosis because it can mask the underlying disease process (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). If symptoms occur, Reglan should be discontinued immediately and medical attention sought (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Once present, TD tends to persist despite dose adjustment or discontinuation of the causative agent (https://pubmed.ncbi.nlm.nih.gov/34703232/). The timeline between exposure to Reglan and the development of TD can vary. While the risk increases with longer treatment duration and higher cumulative doses, TD can occur after relatively short exposure. A case report describes a postoperative gynecological patient who developed dyskinetic movements after a single intraoperative dose of metoclopramide (https://pubmed.ncbi.nlm.nih.gov/34712535/). This patient was found to have several risk factors for TD (https://pubmed.ncbi.nlm.nih.gov/34712535/). Older age is associated with increased risk of TD and with the emergence of TD after shorter treatment durations and lower dosages of DRBAs (https://pubmed.ncbi.nlm.nih.gov/34703232/). While TD can affect people of all ages, older persons are particularly vulnerable (https://pubmed.ncbi.nlm.nih.gov/34703232/).

Causation and Legal Considerations

The adequacy of warnings regarding Reglan and TD is addressed by the FDA's boxed warning, which is the strongest safety warning the agency can issue. The warning clearly states the risk of TD, its potential irreversibility, and the need for short-term use and monitoring. However, despite these warnings, cases of TD continue to occur, including after single-dose administration (https://pubmed.ncbi.nlm.nih.gov/34712535/). This suggests that while the warnings are present, their effectiveness in preventing all cases is limited, particularly in patients with underlying risk factors. For affected patients, causation considerations are important. The link between Reglan and TD is well-established through the drug's mechanism as a dopamine D2-receptor blocking agent (https://pubmed.ncbi.nlm.nih.gov/34712535/). The FDA's boxed warning explicitly states that metoclopramide can cause TD (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397). Patients who develop TD after Reglan use may have a basis for claiming that the drug caused their condition, especially if they were not adequately warned or if they used the drug for longer than recommended. However, individual risk factors, such as older age or pre-existing conditions, may also contribute (https://pubmed.ncbi.nlm.nih.gov/34703232/). The occurrence of TD after a single dose, while rare, demonstrates that even short-term use carries some risk (https://pubmed.ncbi.nlm.nih.gov/34712535/). In summary, Reglan is a known cause of TD, a potentially irreversible movement disorder. The FDA has issued strong warnings about this risk, emphasizing short-term use and monitoring. Despite these warnings, cases continue to occur, including after brief exposure. Patients who develop TD after Reglan use should consider the drug as a likely cause, particularly if other risk factors are present. The timeline between exposure and harm can range from a single dose to months of treatment, with older patients at higher risk for earlier onset.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

What is the link between Reglan and Tardive Dyskinesia?

Reglan (metoclopramide) is a dopamine D2-receptor blocking agent that can cause tardive dyskinesia (TD), a potentially irreversible movement disorder. The FDA has issued a boxed warning about this risk (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=de55c133-eb08-4a35-91a2-5dc093027397).

How long does it take for Tardive Dyskinesia to develop after Reglan use?

The timeline varies. While risk increases with longer treatment and higher cumulative doses, TD can occur after a single dose, as reported in a case study (https://pubmed.ncbi.nlm.nih.gov/34712535/). Older patients are at higher risk for earlier onset (https://pubmed.ncbi.nlm.nih.gov/34703232/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Reglan exposure and a confirmed Tardive Dyskinesia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.